Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

COMPLETED

Identifier: CI-TRIAL-00080395
Entity page: /trial/NCT03971474 ↗
Edges: 11

Neighbours: 2 cancers5 drugs
Drawn: 7 of 7 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) condition of …CONDITION_OFderived4 of 4
← condition of	Lung Non-Small Cell Carcinoma registry condition “Recurrent Lung Non-Small Cell Carcinoma” mapped CURATED_BROADER	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
← condition of	Malignant Lung Neoplasm registry condition “Stage IVA Lung Cancer AJCC v8” mapped CURATED_BROADER

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) intervention of …INTERVENTION_OFderived7 of 7
← intervention of	Docetaxelsmall molecule registry intervention “Docetaxel” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Gemcitabinesmall molecule registry intervention “Gemcitabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Gemcitabinesmall molecule registry intervention “Gemcitabine Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “Pembrolizumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pemetrexedsmall molecule registry intervention “Pemetrexed” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pemetrexedsmall molecule registry intervention “Pemetrexed Disodium” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ramucirumabmonoclonal antibody registry intervention “Ramucirumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) intervention of …INTERVENTION_OFderived7 of 7

← intervention of

Docetaxelsmall molecule

registry intervention “Docetaxel” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Gemcitabinesmall molecule

registry intervention “Gemcitabine” (DRUG) mapped ALIAS

—